Last updated: February 17, 2026
What is NDC 43547-0382?
NDC 43547-0382 corresponds to Bupropion Extended-Release (SR) or XL formulations, primarily marketed as an antidepressant and smoking cessation aid. It is manufactured by Teva Pharmaceuticals.
Market Size and Demand Trends
-
Global Market: The antidepressant and smoking cessation markets have shown consistent growth driven by increasing prevalence of depression, anxiety, and smoking-related health issues.
-
United States Data: The U.S. accounts for approximately 75% of global antidepressant sales. In 2022, antidepressant prescriptions in the U.S. totaled around 45 million, with a steady CAGR of approximately 2-3% through 2023-2025.
-
Market Share: Bupropion formulations hold about 12% of the antidepressant market, ranking behind SSRIs (e.g., sertraline, escitalopram) but ahead of other atypicals.
Competitive Landscape
-
Key Competitors:
- Generic bupropion (e.g., Wellbutrin SR, Zyban)
- Brand-name Wellbutrin XL
- Alternatives for smoking cessation (e.g., varenicline, nicotine replacement therapy)
-
Patent and Exclusivity:
- Bupropion's original patents expired in 2008-2010.
- Teva's formulation may benefit from any remaining exclusivity or patent extensions, but generic competition is strong.
Regulatory and Pricing Environment
-
Pricing Benchmarks:
- Brand-Name Wellbutrin XL: Average wholesale price (AWP) around $380–$420 per month for a typical dose.
- Generic bupropion XL: Wholesale acquisition cost approximately $50–$60 monthly.
- Teva’s specific formulation (NDC 43547-0382): Price closely aligns with generics, typically within the $50–$80 range, depending on quantity and pharmacy discounts.
-
Reimbursement:
- Commercial insurance reimburses approximately 80-90% of drug costs.
- High copays for brand-name drugs push usage toward generics.
Price Projections (Next 5 Years)
| Year |
Projected Price Range (per unit/month) |
Assumptions |
| 2023 |
$50–$80 |
Current generic market, strong competition |
| 2024 |
$50–$85 |
Slight increase due to inflation, manufacturing costs |
| 2025 |
$52–$88 |
Slight market shifts, demand stabilizes |
| 2026 |
$55–$90 |
Market saturation, pricing stabilization |
| 2027 |
$55–$92 |
Price elasticity limits significant increases |
Factors Impacting Future Prices
- Generic Competition: Entry of new generics typically drives prices downward.
- Manufacturing Costs: Slight increases due to raw material prices, regulatory compliance.
- Reimbursement Policies: Shifts toward value-based pricing could influence retail prices.
- Patent Litigation or New Formulations: Potential patent disputes or new delivery forms could temporarily alter pricing.
Summary
NDC 43547-0382 is a generic bupropion formulation with stable, competitive pricing. The market remains highly competitive, constraining significant price increases. Expect minimal upward pressure barring patent disputes or new formulations. Price stability is forecasted within the $50–$90 range over the next five years.
Key Takeaways
- The drug faces intense generic competition, limiting price increases.
- U.S. prescription volume remains steady, supporting consistent demand.
- Prices are unlikely to exceed $100/month without regulatory or patent changes.
- Market trends favor price stability with slight increases aligned with inflation.
- Reimbursement rates and insurance coverage significantly influence retail prices.
FAQs
1. How does generic competition affect the price of NDC 43547-0382?
Generic entry reduces prices through increased supply and market share, typically bringing cost closer to $50–$60 per month.
2. What is the outlook for demand in the coming years?
Demand in the U.S. remains stable, driven by ongoing prevalence of depression and smoking cessation needs.
3. Are there any patent protections that could influence pricing?
Current patents expired around 2010. No recent patent extensions are noted for this formulation.
4. How does insurance coverage impact the retail price?
Insurance tends to reimburse 80-90%, thereby reducing out-of-pocket costs and influencing drug choice towards cheaper generics.
5. What external factors could alter the price projections?
Regulatory changes, new competition, patent disputes, or policy shifts toward value-based reimbursement could impact prices.
References
- IQVIA. (2022). U.S. Prescription Drug Trends.
- FDA. (2023). Approved Drug Products: Bupropion.
- GoodRx. (2023). Bupropion Prices and Cost Comparison.
- EvaluatePharma. (2022). Global Antidepressant Market Report.
- SSRHealth. (2023). Generic Drug Price Trends.
[1] - FDA database.
